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tefano De Servi, MD, FESC,* Matteo Mariani, MD,* Giuseppe Mariani, MD,* Antonino Mazzone, MD†
egnano (Milan), Italy
A crucial point in understanding the clinical and pathophysiologic meaning of C-reactive
protein (CRP) elevation in acute coronary syndromes (ACS) is whether CRP release is
predominantly a response to even small amounts of myocardial necrosis, for which troponin
is a sensitive and specific marker, or is an independent indicator of the inflammatory process
occurring in that clinical condition. Whereas troponin is a good predictor of both mortality
and myocardial infarction (MI), although the highest values are associated with a decreased
probability of MI, CRP predicts mortality but has no relation with the early or late occurrence
of MI. The large variability of CRP values in ACS may depend on the different response of
this inflammation marker to various stimuli, some patients being particularly hyperresponsive,
especially those with elevated CRP values at baseline. We hypothesize that myonecrosis, as
detected by troponin increases, would represent the strongest stimulus for CRP increase in
ACS, causing in some patients, especially those with already-elevated CRP values at baseline,
a disproportionate increase of this marker. Accordingly, the highest CRP values during ACS
are likely to be observed in patients with already-elevated CRP values at baseline (which
would increase the probability of having death and MI in the follow-up) and the highest
troponin values (which would increase the probability of death in the follow-up, but not of
subsequent MI). This hypothesis would explain why high CRP levels in unstable coronary
disease are good predictors of death, but not of MI. (J Am Coll Cardiol 2005;46:1496–502)
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.05.083© 2005 by the American College of Cardiology Foundation
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dcute coronary syndromes (ACS) result from coronary
hrombosis occurring at sites of plaque rupture or superficial
rosion (1–3). Plaques prone to rupture are characterized by
large lipid core, a thin fibrous cap, and an active inflam-
atory cell infiltrate, particularly located underneath dis-
upted portions of the cap, formed by monocyte-derived
acrophages and by increased numbers of activated T
ymphocytes and mast cells (4–6). These cells, once acti-
ated, produce proteolytic enzymes capable of degrading the
ollagen of the fibrous cap, halt collagen synthesis by
mooth muscle cells, and regulate tissue factor production,
epresenting the link between arterial inflammation and
hrombosis (6).
Elevation of inflammatory markers is a common finding
n non–ST-segment elevation ACS. Our group has reported
ome of the earliest observations on leukocyte function and
nflammation in coronary artery disease (7–11), showing an
ncrease of the leukocyte CD11b/CD18 receptor (a glyco-
rotein complex involved in the adhesion process of neu-
rophils and monocytes to endothelial cells) in the coronary
inus of patients with unstable angina, substantiating the
ypothesis that an inflammatory component plays a role in
he pathogenesis of this clinical manifestation (10–11). This
From the Departments of *Cardiovascular Disease and the †Internal Medicine,
spedale Civile di Legnano, Legnano (Milan), Italy.f
Manuscript received April 13, 2005; revised manuscript received May 27, 2005,
ccepted May 31, 2005.bservation stimulated further studies aimed at assessing the
echanism underlying the inflammatory outburst in such
atients (12,13). Therefore we measured the expression of
he CD11b/CD18 receptor, not only in the aorta and in the
oronary sinus, but also in the post-obstructive chamber,
mmediately below the coronary narrowing identified as the
ulprit lesion (12). An increased expression of the CD11b/
D18 receptor was shown in the coronary sinus of these
atients as compared with the aortic blood, whereas neu-
rophils and monocytes taken from the post-obstructive
hamber showed an expression of the CD11b/CD18 recep-
or that did not differ from that shown by those leukocytes
n the aortic blood. We concluded that activation of
eutrophils and monocytes takes place at the microcircula-
ory interface with the injured myocardium, probably as a
esult of short but repeated episodes of myocardial ischemia.
sing a similar approach, Cusack et al. (13) showed that
nterleukin (IL)-6 and tissue necrosis factor (TNF)-alpha
evels were greater in the coronary sinus compared with the
ortic root in unstable angina patients, suggesting intramyo-
ardial production of these substances. Interestingly, the
ntracardiac gradient of these cytokines was found in pa-
ients with elevated troponin T levels, whereas it was no
onger evident in those who were troponin negative. More-
ver, in patients in whom blood samples had also been taken
istal to the culprit coronary lesion, no differences were
ound in the levels of IL-6 and TNF-alpha between the
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October 18, 2005:1496–502 CRP in Unstable Coronary Diseaseroximal and distal coronary artery despite the presence of a
ranscardiac cytokine gradient between the aortic root and
he coronary sinus. These investigators concluded that the
ource of cytokine production lies within the myocardium
nd occurs in response to microinfarctions, as detected by
ncreased troponin levels.
-REACTIVE PROTEIN AS
MARKER OF CORONARY INSTABILITY
mong the various markers of inflammation proposed to
onitor the clinical course of patients with non–ST-segment
levation ACS, C-reactive protein (CRP), an acute-phase
eactant produced by hepatocytes in response to stimulation
y inflammatory cytokines, primarily IL-6, is the most
idely used. Although CRP levels may remain stable over
ong periods of time, they can increase several hundred-fold
n response to inflammatory stimuli and are therefore useful
n following up the disease activity in chronic conditions
uch as rheumatoid arthritis, systemic lupus erythematosus,
nd inflammatory bowel diseases (14). Its use in unstable
ngina was proposed by Liuzzo et al. (15), who found that
evels of CRP 3 mg/l on admission predicted a dire
n-hospital outcome in 32 patients with that clinical condi-
ion.
Further observations underlined that CRP values un-
ergo a dynamic process during hospitalization in such
atients: Ferreiros et al. showed that (16), among 30
atients with values3 mg/l on admission, values remained
bove that level in 12 patients, whereas they decreased in the
emaining 18 patients. On the other hand, of 75 patients
ith CRP levels 3 mg/l on admission, elevated values
eveloped in 30 patients, whereas in 45 patients values
emained below the threshold of 3 mg/l (16). Discharge
RP values, and not admission values, were significantly
elated to the three-month outcome. Likewise, Biasucci et
l. (17) found that elevated levels of CRP on discharge were
ignificant predictors of recurrent instability in the next year.
The popularity of CRP as a marker of inflammation was
urther prompted by observations implicating CRP in vas-
ular dysfunction and in the progression of atherosclerosis.
asceri et al. (18) showed that incubation with recombinant
uman CRP induces a 10-fold increase in adhesion mole-
ule expression in human endothelial cells, similar to that
nduced by activation with IL-1-beta, suggesting that such
Abbreviations and Acronyms
ACS  acute coronary syndrome
CI  confidence interval
CRP  C-reactive protein
IL  interleukin
MI  myocardial infarction
OR  odds ratio
TNF  tumor necrosis factorroinflammatory effects may contribute to the adverse out- iome associated with higher levels of this acute-phase
eactant. Moreover, CRP has been shown to attenuate the
roduction of nitric oxide and prostacyclin by endothelial
ells, supporting its role in the atherosclerotic process
19,20).
A crucial point in understanding the clinical and patho-
hysiologic meaning of CRP elevations in non–ST-segment
levation ACS is whether CRP release is predominantly a
esponse to even small amounts of myocardial necrosis, for
hich troponin is a sensitive and specific marker, or is an
ndependent indicator of the inflammatory process occur-
ing in the coronary arteries in that clinical condition (21).
he issue was addressed by Liuzzo et al. (22), who reported
erial levels of CRP up to 96 h in 48 patients with unstable
ngina (all with troponin levels below 0.1 g/l) and in 20
ontrol patients with variant angina. On admission, the
RP level was significantly higher in unstable angina than
n variant angina, although Holter monitoring showed a
ignificantly greater total ischemic burden in the latter group
f patients. However, ischemic episodes were longer in the
nstable angina group than in the variant angina group. The
emporal relation between changes in CRP and troponin
as studied by Benamer et al. (23) in 195 patients with
nstable angina. These investigators found a temporal link
etween early troponin I increases and later CRP elevations:
n patients with increased troponin I on admission, CRP
evels increased over the following 24 h, whereas in patients
ith normal troponin I on admission, CRP values remained
nchanged. Likewise, using serial sampling, Cusack et al.
13) found that IL-6 and troponin concentrations increased
n parallel over 48 h after hospital admission, suggesting a
lose relationship between systemic inflammatory activity
nd myocardial necrosis. The importance of serial sampling
n unraveling the relationship between troponin and CRP is
lso underlined by Kennon et al. (24), who showed that
RP levels before discharge were correlated with troponin
oncentrations and predicted adverse outcome, whereas
RP levels drawn at admission (6 h after symptom onset)
ere related to neither troponin concentration nor the
ccurrence of adverse events.
ROGNOSTIC VALUE OF CRP AND
TS RELATIONSHIP TO TROPONIN CONCENTRATION
he crucial issue, however, revolves around the prognostic
ole of CRP in non–ST-segment elevation ACS and its
ndependence from troponin values. In their pioneering
ork, Liuzzo et al. (15) reported that CRP was a significant
redictor of outcome unrelated to myocardial injury, be-
ause patients considered to be troponin-positive (that is,
ith values 0.2 g/ml) were excluded from the study.
ikewise, in the Thrombolysis In Myocardial Infarction
TIMI) 11B substudy, Morrow et al. (25) confirmed the
hort-term prognostic value of CRP in ACS; this inflam-
atory marker was related to the 14-day mortality rate, evenn patients with a negative result on rapid troponin T assay,
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CRP in Unstable Coronary Disease October 18, 2005:1496–502hich had a detection limit of 0.2 g/l. These studies,
owever, cannot be considered sufficient proof of the inde-
endence of CRP from troponin values. In fact, a careful
nalysis of the FRagmin and Fast Revascularization during
nStability in coronary artery disease (FRISC) II trial data
26) showed that even small amounts of released troponin T
ave important prognostic implications: the 1-year death
ate was twice as high in patients with troponin values
etween 0.01 and 0.17 g/l as compared with patients with
oncentrations 0.01 g/l. Therefore, patients who were
efined in earliest reports as “troponin negative” because
hey had values 0.2 g/l might have had detectable
oncentrations of troponin T carrying important prognostic
nformation. Another interesting finding of that analysis
as the demonstration of a significant gradient of increasing
isk of myocardial infarction (MI) up to concentrations of
.63 g/l, above which the risk of infarction dramatically
ecreased (26). Such a U-shaped relationship has been
xplained by the fact that patients with the highest troponin
oncentrations have already had a significant MI and are less
igure 1. Relationship between C-reactive protein (CRP) and troponin
alues in 7,108 patients included in the GUSTO IV trial. Data from James
t al. (28).igure 2. Death (left) and myocardial infarction (MI) rate (right) according to in
ncluded in the GUSTO IV trial. qrtl.  quartile. Data from James et al. (28).ikely to have unstable coronary lesions and sizable amounts
f myocardium at risk (27).
Recent studies have attempted to unfold the complex
elationship between CRP and troponin values in predicting
he outcomes of patients with non–ST-segment elevation
CS. A major contribution was provided by the Global
tilization of Strategies to Open occluded arteries
GUSTO) IV study group, reporting the 30-day follow-up
ata in 7,108 patients with non–ST-segment elevation ACS
28). Figure 1 shows the relationship between values of
roponin T and CRP values in that analysis. It is evident
hat patients with the largest increases of CRP values (those
n the fourth quartile) had median troponin T concentra-
ions that were three times as high as those observed in
atients in the third CRP quartile. Although by multivariate
nalysis both increasing troponin T quartiles and increasing
RP quartiles gave an independent contribution to 30-day
ortality, adjusted odds ratios (OR) were higher for tropo-
in T (OR, 1.63; 95% confidence interval [CI], 1.43 to
.87) than for CRP (OR, 1.19; 95% CI, 1.05 to 1.35). A
urprising finding of that report was that, contrary to
roponin, CRP values were not related to the 30-day MI
ate. Figure 2, taken from the data presented in the
USTO IV analysis (28), shows that at increasing levels of
oth CRP and troponin, the risk of mortality similarly
ncreases, whereas the risk of MI increases at increasing
roponin concentrations (although depicting the above-
entioned U-shaped relationship) but is not influenced by
RP levels. The superiority of troponin over CRP in
ssessing outcome in patients with non–ST-segment eleva-
ion ACS may account for the fact that troponin but not
RP is helpful in therapeutic triage of such patients by
dentifying those who will benefit from an invasive over a
onservative strategy (29) or a particular antithrombotic
reatment (30,31).
Other studies based on large populations have assessed
he role of CRP in predicting short-term and long-termcreasing values of C-reactive protein (CRP) and troponin in 7,108 patients
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October 18, 2005:1496–502 CRP in Unstable Coronary Diseaseutcome in non-ST-elevation ACS (32–36) (Table 1). In
hese studies, CRP levels were measured after the events
ualifying for the inclusion (GUSTO IV trial, 9.5 h; C7E3
ab Antiplatelet Therapy in Unstable Refractory Angina
CAPTURE] trial, 8.7 h; FRISC trial, 5.5 h; Mueller et al.
35], not available) when the potential effects of myonecro-
is on CRP levels were already present. The results of these
tudies are consistent in showing that CRP is able to predict
ortality even though the highest odds ratios were observed
or those studies that used a high cutoff level for troponin
0.10 g/l). However, when death and MI were analyzed in
ombination, no significant relationship was found between
RP values and the combined end point. Only in the
APTURE trial was CRP related to an increased cardiac
isk represented by the combination of death and MI (34).
owever, the relative contribution of each variable to the
nal result is unknown because a separate analysis for
ortality alone was not conducted. Moreover, troponin was
ichotomized at the concentration of 0.10 g/l and not
nalyzed as a continuous variable. All of these large studies
onsistently show that CRP levels do not predict the
ccurrence of MI in the follow-up of patients with non–
T-segment elevation ACS (37).
IFFERENT IMPLICATIONS OF TROPONIN AND
RP INCREASE IN NON–ST-SEGMENT ELEVATION ACS
igure 2 outlines the different prognostic significance of
hese two markers. Troponin is a good predictor of both
ortality and MI, even though at the highest concentra-
ions its ability to predict MI is lessened. The highly
ignificant gradient of increasing risk of mortality with
ncreasing troponin levels is dependent on the progressive
eterioration of left ventricular function with increasing
roponin release (26,27). Moreover, positive troponin con-
entrations are associated with more visible thrombus and
omplex anatomy, reflecting the instability of coronary
esions and their propensity toward vessel occlusion, causing
cute MI (38,39). On the other hand, CRP predicts
ortality well, but has no relationship with the early or late
ccurrence of MI, making it very unlikely that the promi-
ent CRP increases seen in patients with ACS would be in
reat part caused by the inflammatory process taking place
n the coronary arteries, leading to plaque rupture or
able 1. Overview of Large Studies Assessing the Prognostic Val
Author (Ref.), Trial n
Mean
Follow-Up
oss et al. (32), FRISC 965 5 months
indahl et al. (33), FRISC 917 37 months
eeschen et al. (34), CAPTURE 447 6 months
ueller et al. (35) 1,042 20 months
ames et al. (28), GUSTO IV 7,108 30 days C
ames et al. (36), GUSTO IV 6,809 1 yr
Troponin values dichotomized at 0.18 g/l; †using a troponin cutoff value of 0.10
ACS  acute coronary syndromes; CI  confidence interval; CRP  C-reactiveormation of coronary thrombi. rIn this regard, it is interesting to analyze the variations
bserved in the CRP values one month after enrolment in
ecent ACS trials (40,41). Over that period of time, in the
to Z trial (40), CRP levels decreased similarly in the
lacebo group (from 20.4 to 2.5 mg/l) and in the group
nitially treated with 40 mg simvastatin (from 20.1 to 2.4
g/l) despite a pronounced difference in low-density li-
oprotein cholesterol (122 mg/dl in the placebo group and
8 mg/dl in the simvastatin group). Further decreases of
RP in the subsequent two-year follow-up period were
ore evident in the group taking 80 mg simvastatin than in
he group taking 20 mg simvastatin and were associated
ith a lower cardiovascular mortality (4.1% vs. 5.4%). In the
ravastatin or Atorvastatin Evaluation and Infection Ther-
py (PROVE IT)-TIMI 22 trial (41), a lower-risk ACS
opulation was enrolled an average of seven days after ACS:
n this already-stabilized population, CRP levels at one
onth decreased more in the 80 mg atorvastatin group
from 12.3 to 1.3 mg/l) than in the 40 mg pravastatin group
from 12.3 to 2.1 mg/l) and were associated with a lower
wo-year coronary heart disease mortality (1.1% vs. 1.4%)
42). Taken together, these data show that the high values
f CRP observed in ACS before clinical stabilization, as in
he A to Z trial, decrease markedly (80% to 90% from their
eak value) during the first month after the acute episode
nd are scarcely influenced, at least initially, by statin
reatment. On the other hand, further decreases of CRP,
ver long stable phases of coronary disease, can be more
requently achieved using high doses of statins and have
eneficial effects on cardiovascular events confirming that
nder stable clinical conditions CRP, as a key marker of
nflammation, is an important determinant of cardiovascular
isk. Indeed, among patients who achieved after one month
f statin treatment low-density lipoprotein cholesterol levels
f 70 mg/dl, those who had CRP levels 2 mg/l had a
orse prognosis than patients who reached values below
hat threshold value (42). Another interesting finding of
hese large studies is the huge variability of CRP values in
CS patients. In the A to Z trial, the admission median
alues of CRP were 20.1 and 20.4 mg/l in the two study
rms, with 25th and 75th percentile values ranging from 7.7
o 43.4 mg/l (40). Such a wide range of values may depend
n the fact that CRP levels in ACS patients increase in
C-Reactive Protein in Non–ST-Segment Elevation ACS
Cutoff
(mg/l)
End Point Death
Adjusted OR (95% CI)
End Point Death  MI
Adjusted OR (95% CI)
10 3.46 (1.51–7.92) 1.35 (0.92–1.98)
10 2.6 (1.5–4.5) ND
10 ND 1.97 (1.21–3.59)*
10 4.1 (2.3–7.2)† ND
uartiles 1.19 (1.05–1.35) 1.07 (0.87–1.31)
10 1.5 (1.15–2.0) ND
the multivariate analysis.
in; MI  myocardial infarction; ND  not determined; OR  odds ratio.ue of
CRP
Level




RP q
esponse to various factors. As shown by Liuzzo et al. (43),
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CRP in Unstable Coronary Disease October 18, 2005:1496–502atients with unstable angina react differently to various
timuli, including coronary angiography and angioplasty.
hese investigators found a significant close correlation
etween the baseline levels of CRP and their increase after
oronary angioplasty and coronary angiography, indicating
hat patients with already-elevated CRP values at baseline
how hyperresponsiveness of this inflammation marker to
hese stimuli (43). Likewise, patients with acute MI pre-
eded by pre-infarction angina who had higher admission
RP values than patients with unheralded MI also had
igher peak CRP values during hospitalization, despite the
act that the necrotic insult, assessed by CK peak levels, was
imilar in the two groups of patients (44). Although the
actors underlying the hyperresponsiveness of some patients
ith unstable angina are unknown, probably involving
cquired and/or genetic mechanisms (45), it seems reason-
ble to conclude from the available data (43,44) that
levated baseline levels of CRP are markers of such hyper-
esponsiveness. Figure 3 shows the possible relationship in
CS patients between their CRP values at baseline and the
alues achieved during ACS. The large variability of CRP
alues depends on the different response to various provoc-
tive stimuli, according to CRP baseline levels and to the
ntensity of the pro-inflammatory stimuli. We hypothesize
hat myonecrosis, as detected by troponin increases, would
epresent the strongest stimulus for CRP increase in ACS,
esulting in some patients in a disproportionate increase of
his marker. Accordingly, the highest CRP values during
CS are likely to be observed in patients with already-
levated CRP levels at baseline (which would increase the
robability of having a new coronary event in the follow-up,
ncluding death and MI) and the highest troponin values
igure 3. Levels of C-reactive protein (CRP) increase in patients with
cute coronary syndromes (ACS) as compared with their baseline levels.
his increase, as well as the variability, is greater for hyperresponsive
atients, who are those with elevated CRP values at baseline; see text for
etails.which would increase the probability of death in the Aollow-up, but not of subsequent MI). This hypothesis
ould explain why high CRP levels in unstable coronary
isease are good predictors of death but not of MI. Further
upport for this hypothesis comes from the observation
ade by the European Concerted Action on Thrombosis
nd Disabilities (ECAT) Angina Pectoris Study, showing
hat elevated CRP levels highly correlate with low left
entricular ejection fraction (46). Surprisingly, no other
tudies have assessed the relationship between CRP levels
nd left ventricular function. A possible influence of de-
ressed LV function on maintaining high CRP levels
uring stable phases of ischemic heart disease should also be
onsidered, because circulating levels of proinflammatory
ytokines are elevated in patients with heart failure (47).
An alternative explanation for the paradoxical finding of
RP being a predictor for death but not for MI is that CRP
s able to predict only large, fatal MIs and not small,
on-fatal MIs, particularly those defined primarily by car-
iac biomarker elevations that are commonly associated
ith percutaneous revascularization procedures. Because the
ajority of MIs observed in the studies analyzed in Table 1,
ncluding the large GUSTO IV trial (28), were non-fatal,
ossibly related to interventional procedures, the relation-
hip between CRP and MI might have been obscured.
owever, because elevated CRP levels have been shown to
e sensitive predictors of adverse events, including MI, after
ercutaneous treatment (48,49) the methodology used to
iagnose MI should have increased rather than decreased
he ability of CRP to predict MI. It can also be speculated
hat elevated CRP values may favor the occurrence of fatal
rrhythmias, but this intriguing hypothesis awaits confirma-
ion by studies addressing the potential proarrhythmic effect
nduced by elevated CRP values (50).
ONCLUSIONS
t has been shown that CRP levels in the general population
redict future cardiovascular events, including first-ever MI,
troke, and development of peripheral arterial disease (51);
RP may also provide a novel method of targeting statin
herapy in both primary and secondary prevention of MI
nd stroke (52) as well as in the follow-up of stable patients
fter ACS (40–42). However, the levels of CRP in ACS are
everal-fold higher than those observed in the same patients
n waning phases of their coronary disease (40–42). A large
art of such huge increases is likely to reflect the inflamma-
ory outburst secondary to the occurrence of myocardial
ecrosis, the highest values of CRP, which are associated
ith the highest short-term and long-term mortality, being
ound in patients with the largest increase in troponin
oncentrations. High CRP values are independent predic-
ors of death in the follow-up of such patients, but are not
ssociated with a greater risk of MI. These apparently
ontradictory findings may be explained by hypothesizing a
trong influence of troponin values on CRP increase in
CS.
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